Google Co-Founder Sergey Brin Pledges $15M To Psychedelics Research Start-Up
Silicon Valley continues pushing the boundaries of mental health treatment, with Google (NASDAQ:GOOG) co-founder Sergey Brin now financing the development of a hallucinogen derived from a West African shrub.
Brin’s Non-Profit Investment In Psychedelics
Brin is leveraging part of the profits from his 2021 Tesla (NASDAQ:TSLA) stake sale to fund Catalyst4, a non-profit investment vehicle dedicated to innovative treatments and technologies. Catalyst4 has pledged approximately $15 million of a $25 million funding round for the psychedelic start-up Soneira, reported Financial Times citing sources familiar with the issue. Soneira is launching clinical trials to explore ibogaine, a substance present in an African shrub, as a potential treatment for traumatic brain injury (TBI).
Ibogaine’s Historical And Modern Significance
Ibogaine, traditionally used in spiritual rituals by tribes in Gabon, recently garnered interest from western mental health researchers and …